Jason J. Luke, MD, FACP, discusses the treatment landscape of metastatic melanoma.
Jason J. Luke, MD, FACP, associate professor of medicine, Division of Hematology/Oncology, director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the treatment landscape of metastatic melanoma.
This space has seen rapid growth over the past 10 years, explains Luke. In the past, treatment was limited to chemotherapy and interleukin-2.
A number of agents have been approved for the treatment of patients with metastatic disease, including combinations of BRAF and MEK inhibitors, as well as immunotherapy with PD-1 inhibitors alone or in combination with CTLA-4 inhibitors, explains Luke.
These novel treatments have shown an overall survival benefit in the metastatic setting. Now, the field has 5-year overall survival data suggesting that at least 50% of patients who develop metastatic melanoma will live for at least 5 years, concludes Luke.